TRGV4 as A Cancer Treatment Target (G6977)

Target Name: TRGV4

NCBI ID: G6977

TRGV4

Other Name(s): V1S4 | T cell receptor gamma variable 4 | TCRGV4

TRGV4 as A Cancer Treatment Target

TRGV4 (Tumor suppressor gene V4) is a gene that has been identified as a potential drug target (also known as a biomarker) for the treatment of various diseases, including cancer. Researchers have found that TRGV4 plays a crucial role in regulating cell growth and division, and that it is often aberrantly expressed in cancer cells.

TRGV4 is a member of the TGF-β (transforming growth factor beta) family, which is a well-known group of genes that are involved in cell growth, differentiation, and repair. TGF-β genes are involved in the regulation of cellular processes that are critical for normal development and maintenance of tissues and organs.

One of the functions of TRGV4 is to regulate the activity of the transcription factor SMAD (small modal associative DNA-binding protein), which is responsible for promoting the expression of genes that are involved in cell growth and division. When SMAD is activated, it binds to the TRGV4 protein and helps to physically alter its structure, allowing it to interact with other proteins and facilitate the regulation of gene expression.

Research has shown that TRGV4 is often aberrantly expressed in various types of cancer, including breast, ovarian, and colorectal cancer. When TRGV4 is expressed at high levels, it can lead to the development of cancerous tumors. This suggests that targeting TRGV4 with drugs or other therapeutic agents may be an effective way to treat these diseases.

Targeting TRGV4 has the potential to be an effective way to treat various types of cancer because it is involved in the regulation of cell growth and division, which are critical processes for the development and progression of cancer. By inhibiting the activity of TRGV4, researchers may be able to inhibit the growth and spread of cancerous tumors.

In addition to its role in cancer development, TRGV4 is also involved in the regulation of normal cell growth and development. High levels of TRGV4 have been shown to disrupt the normal function of cells, leading to the development of cellular stress and dysfunction. This suggests that targeting TRGV4 with drugs or other therapeutic agents may also be effective in treating a variety of diseases and conditions.

Overall, TRGV4 is a gene that has the potential to be a drug target or biomarker for the treatment of various diseases, including cancer. Further research is needed to fully understand the role of TRGV4 in cell growth and development, and to identify effective ways to target it with drugs or other therapeutic agents.

Protein Name: T Cell Receptor Gamma Variable 4

Functions: V region of the variable domain of T cell receptor (TR) gamma chain that participates in the antigen recognition (PubMed:24600447). Gamma-delta TRs recognize a variety of self and foreign non-peptide antigens frequently expressed at the epithelial boundaries between the host and external environment, including endogenous lipids presented by MH-like protein CD1D and phosphoantigens presented by butyrophilin-like molecule BTN3A1. Upon antigen recognition induces rapid, innate-like immune responses involved in pathogen clearance and tissue repair (PubMed:23348415, PubMed:28920588). Binding of gamma-delta TR complex to antigen triggers phosphorylation of immunoreceptor tyrosine-based activation motifs (ITAMs) in the CD3 chains by the LCK and FYN kinases, allowing the recruitment, phosphorylation, and activation of ZAP70 that facilitates phosphorylation of the scaffolding proteins LCP2 and LAT. This lead to the formation of a supramolecular signalosome that recruits the phospholipase PLCG1, resulting in calcium mobilization and ERK activation, ultimately leading to T cell expansion and differentiation into effector cells (PubMed:25674089). Gamma-delta TRs are produced through somatic rearrangement of a limited repertoire of variable (V), diversity (D), and joining (J) genes. The potential diversity of gamma-delta TRs is conferred by the unique ability to rearrange (D) genes in tandem and to utilize all three reading frames. The combinatorial diversity is considerably increased by the sequence exonuclease trimming and random nucleotide (N) region additions which occur during the V-(D)-J rearrangements (PubMed:24387714)

The "TRGV4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRGV4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets